Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea

Jeongha Mok, Hyungseok Kang, Soo Hee Hwang, Jin Su Park, Bohyoung Kang, Taehoon Lee, Won Jung Koh, Jae-Joon Yim, Doosoo Jeon

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: Delamanid is a new anti-TB drug, but few data exist on its use outside clinical trials. The purpose of this study was to evaluate the efficacy as well as the safety and tolerability of a delamanid-containing regimen for 24 weeks in the treatment of MDR- and XDR-TB. Methods: We performed a retrospective cohort study among patients with MDR/XDR-TB who were treated with a delamanid-containing regimen in seven hospitals in South Korea. Results: A total of 32 patients with MDR-TB, of which 6 (18.8%) were XDR-TB, were included and all completed 24 weeks of delamanid treatment. Of 19 patients (59.4%) who had positive culture sputum at the initiation of delamanid treatment, the proportion of culture conversion at 8 weeks was 72.2% (13 of 18) in solid medium and 50.0% (7 of 14) in liquid medium. The proportion of culture conversion at 24 weeks was 94.4% (17 of 18) in solid medium and 92.9% (13 of 14) in liquid medium. The median time to culture conversion was 33 days (range = 5-81) using solid medium and 57 days (range = 8-96) using liquid medium. Of the 32 patients, there was no serious adverse event or death. Three patients developed a transient QTcF of > 500 ms. Conclusions: The use of delamanid combined with optimized background regimens has the potential to achieve high culture conversion rates at 24 weeks with an acceptable safety and tolerability profile in patients with MDR/XDR-TB.

Original languageEnglish
Pages (from-to)503-508
Number of pages6
JournalThe Journal of antimicrobial chemotherapy
Volume73
Issue number2
DOIs
StatePublished - 1 Feb 2018

Fingerprint

Extensively Drug-Resistant Tuberculosis
Republic of Korea
Safety
Sputum
OPC-67683
Cohort Studies
Therapeutics
Retrospective Studies
Clinical Trials
Pharmaceutical Preparations

Cite this

Mok, J., Kang, H., Hwang, S. H., Park, J. S., Kang, B., Lee, T., ... Jeon, D. (2018). Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea. The Journal of antimicrobial chemotherapy, 73(2), 503-508. https://doi.org/10.1093/jac/dkx373
Mok, Jeongha ; Kang, Hyungseok ; Hwang, Soo Hee ; Park, Jin Su ; Kang, Bohyoung ; Lee, Taehoon ; Koh, Won Jung ; Yim, Jae-Joon ; Jeon, Doosoo. / Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea. In: The Journal of antimicrobial chemotherapy. 2018 ; Vol. 73, No. 2. pp. 503-508.
@article{d73de31320f44d7ab23ec1db28c6af84,
title = "Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea",
abstract = "Objectives: Delamanid is a new anti-TB drug, but few data exist on its use outside clinical trials. The purpose of this study was to evaluate the efficacy as well as the safety and tolerability of a delamanid-containing regimen for 24 weeks in the treatment of MDR- and XDR-TB. Methods: We performed a retrospective cohort study among patients with MDR/XDR-TB who were treated with a delamanid-containing regimen in seven hospitals in South Korea. Results: A total of 32 patients with MDR-TB, of which 6 (18.8{\%}) were XDR-TB, were included and all completed 24 weeks of delamanid treatment. Of 19 patients (59.4{\%}) who had positive culture sputum at the initiation of delamanid treatment, the proportion of culture conversion at 8 weeks was 72.2{\%} (13 of 18) in solid medium and 50.0{\%} (7 of 14) in liquid medium. The proportion of culture conversion at 24 weeks was 94.4{\%} (17 of 18) in solid medium and 92.9{\%} (13 of 14) in liquid medium. The median time to culture conversion was 33 days (range = 5-81) using solid medium and 57 days (range = 8-96) using liquid medium. Of the 32 patients, there was no serious adverse event or death. Three patients developed a transient QTcF of > 500 ms. Conclusions: The use of delamanid combined with optimized background regimens has the potential to achieve high culture conversion rates at 24 weeks with an acceptable safety and tolerability profile in patients with MDR/XDR-TB.",
author = "Jeongha Mok and Hyungseok Kang and Hwang, {Soo Hee} and Park, {Jin Su} and Bohyoung Kang and Taehoon Lee and Koh, {Won Jung} and Jae-Joon Yim and Doosoo Jeon",
year = "2018",
month = "2",
day = "1",
doi = "10.1093/jac/dkx373",
language = "English",
volume = "73",
pages = "503--508",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "2",

}

Mok, J, Kang, H, Hwang, SH, Park, JS, Kang, B, Lee, T, Koh, WJ, Yim, J-J & Jeon, D 2018, 'Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea', The Journal of antimicrobial chemotherapy, vol. 73, no. 2, pp. 503-508. https://doi.org/10.1093/jac/dkx373

Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea. / Mok, Jeongha; Kang, Hyungseok; Hwang, Soo Hee; Park, Jin Su; Kang, Bohyoung; Lee, Taehoon; Koh, Won Jung; Yim, Jae-Joon; Jeon, Doosoo.

In: The Journal of antimicrobial chemotherapy, Vol. 73, No. 2, 01.02.2018, p. 503-508.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea

AU - Mok, Jeongha

AU - Kang, Hyungseok

AU - Hwang, Soo Hee

AU - Park, Jin Su

AU - Kang, Bohyoung

AU - Lee, Taehoon

AU - Koh, Won Jung

AU - Yim, Jae-Joon

AU - Jeon, Doosoo

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Objectives: Delamanid is a new anti-TB drug, but few data exist on its use outside clinical trials. The purpose of this study was to evaluate the efficacy as well as the safety and tolerability of a delamanid-containing regimen for 24 weeks in the treatment of MDR- and XDR-TB. Methods: We performed a retrospective cohort study among patients with MDR/XDR-TB who were treated with a delamanid-containing regimen in seven hospitals in South Korea. Results: A total of 32 patients with MDR-TB, of which 6 (18.8%) were XDR-TB, were included and all completed 24 weeks of delamanid treatment. Of 19 patients (59.4%) who had positive culture sputum at the initiation of delamanid treatment, the proportion of culture conversion at 8 weeks was 72.2% (13 of 18) in solid medium and 50.0% (7 of 14) in liquid medium. The proportion of culture conversion at 24 weeks was 94.4% (17 of 18) in solid medium and 92.9% (13 of 14) in liquid medium. The median time to culture conversion was 33 days (range = 5-81) using solid medium and 57 days (range = 8-96) using liquid medium. Of the 32 patients, there was no serious adverse event or death. Three patients developed a transient QTcF of > 500 ms. Conclusions: The use of delamanid combined with optimized background regimens has the potential to achieve high culture conversion rates at 24 weeks with an acceptable safety and tolerability profile in patients with MDR/XDR-TB.

AB - Objectives: Delamanid is a new anti-TB drug, but few data exist on its use outside clinical trials. The purpose of this study was to evaluate the efficacy as well as the safety and tolerability of a delamanid-containing regimen for 24 weeks in the treatment of MDR- and XDR-TB. Methods: We performed a retrospective cohort study among patients with MDR/XDR-TB who were treated with a delamanid-containing regimen in seven hospitals in South Korea. Results: A total of 32 patients with MDR-TB, of which 6 (18.8%) were XDR-TB, were included and all completed 24 weeks of delamanid treatment. Of 19 patients (59.4%) who had positive culture sputum at the initiation of delamanid treatment, the proportion of culture conversion at 8 weeks was 72.2% (13 of 18) in solid medium and 50.0% (7 of 14) in liquid medium. The proportion of culture conversion at 24 weeks was 94.4% (17 of 18) in solid medium and 92.9% (13 of 14) in liquid medium. The median time to culture conversion was 33 days (range = 5-81) using solid medium and 57 days (range = 8-96) using liquid medium. Of the 32 patients, there was no serious adverse event or death. Three patients developed a transient QTcF of > 500 ms. Conclusions: The use of delamanid combined with optimized background regimens has the potential to achieve high culture conversion rates at 24 weeks with an acceptable safety and tolerability profile in patients with MDR/XDR-TB.

UR - http://www.scopus.com/inward/record.url?scp=85047016255&partnerID=8YFLogxK

U2 - 10.1093/jac/dkx373

DO - 10.1093/jac/dkx373

M3 - Article

C2 - 29069496

AN - SCOPUS:85047016255

VL - 73

SP - 503

EP - 508

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 2

ER -